Design, synthesis and molecular docking of α,β-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 2, 2013, Pages 388-394

  Xu, Yun Yun ^a   Cao, Yi ^a   Ma, Hailkuo ^a   Li, Huan Qiu ^a   Ao, Gui Zhen ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

, Unsaturated cyclohexanone analogous; Antiproliferative; Curcumin; EGFR; Molecular docking

Indexed keywords

2 (2 BROMOBENZYLIDENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (2 CHLOROBENZYLIDENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3 BROMOBENZYLIDENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3 CHLOROBENZYLIDENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3,4 DIHYDROXYBENZYLIDENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 (2 FLUOROBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 (2 METHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 (3 HYDROXY 4 METHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 (3 METHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 (4 FLUOROBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 (4 HYDROXYBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 (4 METHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 [4 (DIMETHYLAMINO)BENZYLIDENE]CYCLOHEXANONE; 2 (3,5 DIMETHOXYBENZYLIDENE) 6 [4 (METHYLSULFONYL)BENZYLIDENE]CYCLOHEXANONE; 2 (4 BROMOBENZYLIDENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (4 CHLOROBENZYLIDENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 (4 CYCLOHEXYLMETHYLENE) 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2 BENZYLIDENE 6 (3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(3,5 DIMETHOXYBENZYLIDENE)CYCLOHEXANONE; ALPHA,BETA UNSATURATED CYCLOHEXANONE DERIVATIVE; CURCUMIN; CYCLOHEXANONE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; CYCLOHEXANONES; DRUG DESIGN; HEP G2 CELLS; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871631060     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.11.031     Document Type: Article

References (27)

1. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Science 235 1987 177
2. D.J. Slamon, W. Godolphin, and L.A. Jones Science (Wash. DC) 244 1989 707
3. D. Scheurle, M. Jahanzeb, R.S. Aronsohn, L. Watzek, and R.H. Narayanan Anticancer Res. 20 2000 2091
4. G. Cox, M. Vyberg, B. Melgaard, J. Askaa, A. Oster, and K.J. O'Byrne Int. J. Cancer 92 2001 480
5. A.J. Bridges Curr. Med. Chem. 6 1999 825
6. D.K. Moscatello, M. Holgado-Mudruga, A.K. Godwin, G. Ramirez, G. Gunn, P.W. Zoltick, J.A. Biegel, R.L. Hayes, and A.J. Wong Cancer Res. 55 1995 5536
7. C.J. Wikstrand, R.E. McLendon, A. Friedman, and D.D. Bigner Cancer Res. 57 1997 4130
8. D.W. Fry, A.J. Kraker, A. McMichael, L.A. Ambroso, J.M. Nelson, W.R. Leopold, R.W. Connors, and A.J. Bridges Science 265 1994 1093
9. W.H.J. Ward, P.N. Cook, A.M. Slater, D.H. Davies, G.A. Holdgate, and L.R. Green Biochem. Pharmacol. 48 1994 659
10. A.J. Bridges, H. Zhou, D.R. Cody, G.W. Rewcastle, A. McMichael, H.D.H. Showalter, D.W. Fry, A.J. Kraker, and W.A. Denny J. Med. Chem. 39 1996 267
11. A.E. Wakeling, A.J. Barker, D.H. Davies, D.S. Brown, L.R. Green, S.A. Cartlidge, and J.R. Woodburn Breast Cancer Res. Treat. 38 1996 67
12. K. Iwata, P.E. Miller, E.G. Barbacci, L. Arnold, J. Doty, C.I. DiOrio, L.R. Pustilnik, M. Reynolds, A. Thelemann, D. Sloan, and J.D. Moyer Proc. Am. Assoc. Cancer Res. 38 1997 633
13. J.R. Woodburn, A.J. Barker, K.H. Gibson, S.E. Ashton, A.E. Wakeling, B.J. Curry, L. Scarlett, and L.R. Henthorn Proc. Am. Assoc. Cancer Res. 38 1997 633
14. Company Press Release, Feb 1, 2010: GSK's TYKERB receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer.
15. P. Anand, S.G. Thomas, A.B. Kunnumakkara, C. Sundaram, K.B. Harikumar, B. Sung, S.T. Tharakan, K. Misra, I.K. Priyadarsini, K.N. Rajasekharan, and B.B. Aggarwal Biochem. Pharmacol. 76 2008 1590
16. M.T. Huang, Y.R. Lou, and W. Ma Cancer Res. 54 1994 5841
17. S. Mukherjee Nee Chakraborty, U. Ghosh, N.P. Bhattacharyya, R.K. Bhattacharya, S. Dey, and M. Roy Mol. Cell Biochem. 297 2007 31
18. M. Pesic, J.Z. Markovic, D. Jankovic, S. Kanazir, I.D. Markovic, and L. Rakic J. Chemother. 18 2006 66
19. C.H. Hsu, and A.L. Cheng Adv. Exp. Med. Biol. 595 2007 471
20. G. Garcea, D.J. Jones, R. Singh, A.R. Dennison, P.B. Farmer, and R.A. Sharma Br. J. Cancer 90 2004 1011
21. S. Shishodia, M.M. Chaturvedi, and B. Aggarwal Curr. Probl. Cancer 31 2007 243
22. T. Dorai, N. Gehani, and A. Katz Mol. Urol. 4 2000 1
23. G. Liang, L.L. Shao, Y. Wang, C.G. Zhao, Y.H. Chu, J. Xiao, Y. Zhao, X.Y. Li, and S.L. Yang Bioorg. Med. Chem. 17 2009 2623
24. Y. Babasaheb, T. Sebastien, J. Rhonda, S. Marc, D. Marc, J.S. Tiffany, and L. Lesley Bioorg. Med. Chem. 18 2010 6701
25. H. Chandru, A.C. Sharada, B.K. Bettadaiah, C.S. Ananda Kumar, K.S. Rangappa, Sunnila, and K. Jayashree Bioorg. Med. Chem. 15 2007 7696
26. D.S. Jeffrey, G.V.S. Christopher, and W.S. Caldwell J. Med. Chem. 42 1999 3066
27. H.-R. Tsou, N. Mamuya, B.D. Johnson, M.F. Reich, B.C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F.E. Koehn, L.M. Greenberger, Y.-F. Wang, and A. Wissner J. Med. Chem. 44 2001 2719